# Changes in Biomarkers Using Prostaglandin Inhibitors

> **NCT01769625** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hartford Hospital** · enrollment: 31 (actual)

## Conditions studied

- Biomarker Change Linked to Breast Cancer

## Interventions

- **DRUG:** placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU

## Key facts

- **NCT ID:** NCT01769625
- **Lead sponsor:** Hartford Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01769625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01769625, "Changes in Biomarkers Using Prostaglandin Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01769625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*